Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Thermo Fisher (TMO) to $585 from $620 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025
- Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls
- Scotiabank starts coverage on large cap life science tools trio
- Thermo Fisher initiated with a Sector Perform at Scotiabank
- Thermo Fisher price target lowered to $660 from $675 at BofA